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ABSTRACT
The CDC estimates that one in 20 patients admitted to the hospital is a carrier of
methicillin-resistant Staphylococcus aureus (MRSA). Staphylococci are commonly found on the
skin and mucous membranes within the anterior nares, which provides the principle reservoir for
this organism. These organisms can go on to cause surgical site infections in hospitalized
patients.
Mupirocin is an effective topical medication used to eliminate nasal carriage of
Staphylococcus aureus (S. aureus). Based on Level A evidence, the 2007 Society of Thoracic
Surgeons has made a Class I recommendation for the use of mupirocin for all patients
undergoing cardiac surgery in the absence of documentation of a negative culture for
staphylococcal colonization.
The purpose of this before-and-after study is to examine the rates of surgical site
infections (SSI) for cardiac surgery patients who came through the pre-admission testing unit
prior to same-day admission (SDA) for surgery before and after providing 2% mupirocin nasal
ointment.
Specific aims:
1. To examine the relationship between providing mupirocin to the SDA cardiac surgery
patient and the prevalence of SSI.
2. To examine the cost-effectiveness of providing mupirocin to the SDA cardiac surgery
patient and SSI.
3. To examine the adherence of SDA preoperative cardiac surgery patients and the use of
mupirocin preoperatively, if the medication is provided at no cost to the patient.
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Retrospective chart reviews were completed on 330 patients: 175 patients in the preprovision of mupirocin and 150 in the mupirocin provided group. Chi Square and students’ ttests were used to analyze the data.
There were five SSIs in the pre-provision of mupirocin group and no SSIs in the
mupirocin provided group. This was a significantly statistical difference between the groups
(X2[1] = 4.497, p < 0.5)
Continued provision of 2% nasal mupirocin to prevent SSI in the cardiac surgery patients
is recommended.
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CHAPTER ONE: INTRODUCTION
Assessment of Need
Methicillin-resistant Staphylococcus aureus (MRSA) infection in the United States (U.S.)
is a major public health concern. MRSA has been a problem with hospitalized patients since the
1960s. In 2003, 64.4% of hospital-acquired Staphylococcus aureus (S. aureus) infections were
methicillin-resistant (Klevens et al., 2007). MRSA infections are associated with longer lengths
of hospitalization, higher mortality, and increased costs. In cardiac surgery, the incidence of
surgical site infections (SSIs) is generally between 1 – 8%, but mortality rates for those with a
SSIs are high, with a rate around 14 – 47% (Nicholson & Huesman, 2006). Approximately 20%
of these SSI are caused by MRSA, and between 30 – 100% of postoperative wound infections
can be caused by autoinfection with S. aureus (Wenzel & Perl, 1995)
MRSA has now become endemic in many U.S. hospitals. Because of the endemic nature
of the organism, MRSA is considered a risk factor for post-operative SSIs and is associated with
poor clinical outcomes and higher costs of medical care. The Center for Disease Control and
Prevention (CDC) has noted increases in both community- and hospital-acquired MRSA when
comparing the 2001 data to the 2004 data (Centers for Disease Control and Prevention, 2007). In
the United Kingdom, the Department of Health has begun mandatory reporting of MRSA
infections in hospitals (Health Protection Agency, 2007). In the U.S., several states have passed
bills requiring active surveillance for MRSA (General Assembly of Pennsylvania, 2007; Illinois
Senate Bill 0233, 2007; State of New Jersey, Senate Number 2580, & 212th Legislature, 2008).
The Healthcare Infection Control Practices Advisory Committee of the CDC has published
guidelines for expanding surveillance of asymptomatic patients in certain settings (Seigel,
Rhinehart, Jackson, & Chairello, 2006). The 110th Congress of the U.S. introduced Bill S2278IS,
1

which concerns the need to “improve the prevention, detection, and treatment of community and
healthcare-associated infections (CHAI) with a focus on antibiotic-resistant bacteria” (Durbin,
2007). In a recent study, the CDC estimated that nearly 95,000 people became infected with
invasive MRSA in 2005, which resulted in 19,000 deaths (Centers for Disease Control and
Prevention, 2007). The annual nationwide cost to treat all hospitalized patients infected with
MRSA in estimated to be more than $4 billion dollars (State of New Jersey et al., 2008).

Staphylococcus aureus and Treatment with Mupirocin
Staphylococci are commonly found on the skin and mucous membranes, with the anterior
nares providing the principle reservoir for this organism. The suggested pathway for
autoinfection is as follows: S. aureus is present in the anterior nares and then spreads via hand
carriage to other body sites, where the organism can enter into breaks in the skin (Tulloch, 1954;
Wenzel & Perl, 1995). This autoinfection of surgical wounds is common, and since MRSA can
survive on cloth and plastic for up to 90 days, it is frequently transmitted by contaminated hands,
clothes, and non-invasive instruments. The CDC estimates that one in 20 people entering the
hospital carries MRSA (Centers for Disease Control and Prevention, 2007).
Although MRSA is very common in hospitals, it can be prevented by taking certain
precautions. Mupirocin is an effective topical medication that eliminates nasal carriage of S.
aureus. Based on Level A evidence, the 2007 Society of Thoracic Surgeons has made a Class I
recommendation for the use of mupirocin for all patients undergoing cardiac surgery in the
absence of documentation of a negative culture for staphylococcal colonization (Engelman et al.,
2007). Based on this recommendation, preoperative orders to complete nasal cultures on all
cardiac surgery patients and administer mupirocin preoperatively were instituted at this facility.
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This is completed easily when the patient is in-house preoperatively. For patients who are seen in
the office and come to the hospital the same day as surgery, the nasal cultures are done in the
pre-admission testing unit with the other preoperative labs. It was providing these patients with
the preoperative mupirocin that was problematic and where the gap in care occurred.
When implementing the 2% mupirocin nasal ointment prophylaxis project for the sameday surgery admission patient, the process was for the patient to be seen in the office by the
surgeon, who determined if patient was a surgical candidate and who set the surgery date. The
patient was then processed in Pre-Admission Testing (PAT) for preoperative labs, education, and
admission paperwork. MRSA nasal cultures were completed at that time, usually within one to
two days prior to surgery. The patient arrived the morning of surgery, he or she received the
morning dose of mupirocin in preoperative holding, cultures were checked on arrival to the
cardiovascular recovery unit (CVRR), and mupirocin was continued if cultures came back
positive. If the culture’s result was unavailable, the mupirocin was continued until a negative
final culture was determined and the mupirocin was stopped. The problem was with the sameday surgery patient obtaining mupirocin. A prescription for the medication was given at the CV
surgeons’ office visit and the patient could have it filled at any pharmacy. Most pharmacies do
not carry unit-dose (1 dose) 2% mupirocin nasal ointment. The patient would have to find a
pharmacy that carries 2% mupirocin nasal ointment and then would have to purchase a box of 20
tubes of 2% mupirocin nasal ointment to receive one dose of the drug. This was difficult for the
patient to find a pharmacy, expensive, and more medication than was needed by the patient.
Based on the Society of Thoracic Surgeons recommendation of treating all cardiac
surgery patients with 2% mupirocin nasal ointment preoperatively to prevent autoinfection with
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S. aureus (Richard Engelman et al., 2007), the proposed benefits of providing mupirocin to
cardiac surgery same-day admit patients in PAT included but was not limited to:
•

A decrease in surgical site infections in same-day admit cardiac surgery patients that are
nasal carriers of S. aureus, which leads to cost savings related to decrease in length of
stay for patients with surgical site infections and possible reoperations

•

The psychological/psychosocial benefits for same-day admit cardiac surgery patients in
experiencing a positive surgical experience

•

Decrease in overall hospital, staff, and family cross contamination of S. aureus, which
could lead to collateral infections.

The first benefit listed is related to the actual monies saved by preventing a sternal wound
infection to the facility. The cost of caring for a patient with a sternal wound infection post
cardiac surgery is approximately 2.8 times higher than an uncomplicated postoperative cardiac
surgery case (Nicholson & Huesman, 2006). These costs are related to increase in prolonged
hospitalization, increased health care costs, and the potential for decrease in reimbursement from
Medicare due to an undocumented preoperative infection.
The second benefit pertains to the decrease in stress on an already stressed patient by
providing a positive postoperative experience. Surgical complications, such as postoperative
infection, increases patient complaints and dissatisfaction (Murff et al., 2006).
The costs of providing mupirocin to PAT cardiac surgery patients were considered and
include the following:
•

Increase in pharmacy budget to purchase mupirocin. These costs will be determined by
the amount of mupirocin purchased and provided to an estimated number of same-day
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admit cardiac surgery patients. This number is an estimate because the number of cardiac
surgeries is declining yearly. However, the percentage of PAT/same-day cardiac surgery
admits per year has consistently increased.
•

Increase in education material costs due the need to print instructions on mupirocin usage
to provide to the patient when given the medication.

This study will examine the impact of 2% mupirocin nasal ointment prophylaxis on
preoperative cardiac patients that come into the pre-admission testing unit for preoperative
testing prior for same-day admission for cardiac surgery and surgical site infections. The
question to be asked is, if these patients (preoperative same-day cardiac surgery patient) are
provided with 2% mupirocin nasal ointment prophylaxis and given verbal and written
instructions in PAT and the pharmacy staff on administration of the medication, will a decrease
in surgical site infections be observed in the same-day admission cardiac surgery patients? A
related question would be, how many and what is the rate of same-day admission cardiac surgery
patients who are cultured preoperatively have a positive culture?
The question of relevance to nursing knowledge and clinical practice should be addressed
in relationship to the research question. The provision and treatment of all cardiac surgical
patients preoperatively with mupirocin prophylaxis is a standard of care. If it is the facility’s
desire to provide evidenced-based care, then all the patients having cardiac surgery should
receive mupirocin preoperatively. Prevention of surgical site infections is paramount in the
cardiac surgery patient. Developing a sternal wound infection post-operatively is not only
expensive to the organization but can potentially decrease reimbursement from Medicare,
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increase mortality risk for the patient, and decrease patient satisfaction (Murff et al., 2006; U.S.
Department of Health and Human Services, 2007; Wenzel & Perl, 1995).

Objectives and Aims
The objectives of the proposed study are as follows:
1. To examine the relationship between providing mupirocin to the same-day admission
cardiac surgery patient and the prevalence of surgical site infections. This will be
compared using the surgical site infection rate for the year prior to implementing the
project.
2. To examine the cost-effectiveness of providing mupirocin to the same-day admission
cardiac surgery patient and surgical site infections
3. To examine the adherence of same-day preoperative cardiac surgery patients and the use
of mupirocin preoperatively.

The research question used in the project is, is there a reduction in cardiac surgery
surgical site infections after providing 2% mupirocin nasal ointment to the same-day admission
cardiac surgery patients? The variables examined included:
•

MRSA positive cultures done preoperatively in Pre-Admission Testing (PAT) unit

•

2% Mupirocin nasal ointment 1-gram dose

•

Surgical site infection occurring after surgery (immediate to 30 days post operatively)

Co-morbidities examined included: diabetes mellitus (Type 1 or Type 2), obesity, female
gender, tobacco use preoperatively, chronic obstructive pulmonary disease (COPD), presence of
preoperative infection, and use of chlorhexidine gluconate scrub preoperatively. Laboratory
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parameters to be examined included hematocrit (HCT), serum creatinine (Scr), glycoslated
hemoglobin (HGBA1C), and positive culture from other sites. Perioperative factors examined
included receipt and timing of antibiotics, redosing of antibiotics, receipt of preoperative
steroids, lowest core body temperature during surgery, transfusion of blood products, and type of
cardiac surgery performed. Adherence with medication use by the patient preoperatively was
examined.
The proposed question/study reviewed was a quasi-experimental design—a before and
after study design. As such, it utilized a historical comparison group—the same-day admission
cardiac surgery patients’ data from the previous year (2007-2008) compared to the same-day
admission cardiac surgery patients who received the 2% mupirocin nasal ointment, beginning
December 1, 2008. Because of the quasi-experimental design, the independent variable is the use
of 2% mupirocin nasal ointment provided to the same-day admission cardiac surgery patients at
PAT, and the dependent variable is the occurrence of surgical site infections postoperatively in
the same-day cardiac surgery patients who received 2% mupirocin nasal ointment.
The null hypothesis is that there will be no difference in the surgical site infection rate
between the same-day admission cardiac surgery patients who received 2% mupirocin nasal
ointment preoperatively and the same-day admission cardiac surgery patients who did not
receive 2% mupirocin nasal ointment preoperatively. Therefore, the hypothesis is that there is a
difference (a decrease) in surgical site infections in same-day admission cardiac surgery patients
at ORMC will received 2% mupirocin nasal ointment prophylaxis preoperatively and the sameday admission cardiac surgery patients who did not receive 2% mupirocin nasal ointment
prophylaxis preoperatively.
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CHAPTER TWO: LITERATURE REVIEW
This chapter will review the literature in relationship to mupirocin prophylaxis in the
cardiac surgery patient and surgical site infections. The review of the literature focuses on
research findings related to cardiac surgery, surgical site infections, MRSA and cardiac surgery,
and nasal mupirocin prophylaxis in this specific population.

Search Terms and Strategies
The key concepts researched to prepare for the proposed study included: cardiac surgery,
MRSA, and mupirocin prophylaxis treatment. The literature was searched using the keywords:
Methicillin-resistant Staphylococcus aureus, MRSA, hospital-acquired MRSA, MRSA surgical
site infections, cardiac surgery MRSA infections, surgical prophylaxis for MRSA, MRSA
prophylaxis, intranasal MRSA, mupirocin, mupirocin prophylaxis, mupirocin and therapeutic
uses, cardiac surgery, thoracic surgery, and heart surgery. The databases utilized in the search
included: Pubmed, Medline, Cinahl, and CSA/Illumina. Inclusion criteria for article selection
included: English language and adult cardiac surgery population. In the database search, 38,522
articles were identified. Please see Appendix A: Table A1: Literature Search Strategies and
Table A2: Mupirocin Literature Review, for the yield of articles per database. During the search,
several studies were noted to be cited in multiple databases. These articles were included in the
selection and review for the development of the research project.
The review of mupirocin and the effectiveness of the medication in the treatment of nasal
carriage of Staphylococcus aureus in cardiac surgical patients are indicated if this medication is
to be utilized. This section will explore the major studies in nasal carriage of S. aureus and
MRSA, MRSA and cardiac surgery surgical site infections, recommendations regarding the use
8

of mupirocin for prevention and treatment of MRSA in the cardiac patient, mupirocin resistance,
and cost benefit of mupirocin in the cardiac surgery patient.

Nasal Carriage of Staphylococcus aureus and MRSA
As early as 1931, the evidence regarding nasal carriage of Staphylococcus aureus was
found in the literature. Miles (1944) examined the nasal and skin strains of S. aureus and found
them to be the same. Tullock (1954) addressed the relationship with nasal carriage of S. aureus
and staphylococcal skin diseases and determined that the sterilization of the anterior nares was
needed to decrease autoinfection. He did phage typing to confirm the anterior nares as the
primary source of the S. aureus in chronic staphylococcal dermatoses. Kluytmans, Mouton,
Ijzerman, Vandenbroucke-Grauls, Maat, Wagenvoort, et.al (1995) examined nasal carriage of S.
aureus as a risk factor for development of a sternal wound infection after cardiac surgery. All
patients had nasal swabs done the day prior to surgery, and if they developed a sternal wound
infection, the sternal wound was cultured as well. If the sternal wound grew S. aureus, then the
nasal and sternal wound cultures were sent for phage typing. From the study population (1980
patients), 2%, or 40 patients, developed sternal wound infections. In 19 of the 40 cases, the
patients had positive preoperative S. aureus nasal cultures. In 10 out of the 19 cases, the phagetyping showed that the S. aureus isolates were identical (Kluytmans et al., 1995). Munoz,
Hortal, Giannella, Barrio, Roriguez-Creixems, Perez, Rincon, et al. (2007) examined 357
patients undergoing major heart surgery to determine the risk factors that contribute to the
development of surgical site infections after open heart surgery. Nasal cultures were done
preoperatively. They found that approximately 27% of patients scheduled for open-heart surgery
were nasal carriers of S aureus before surgery, and 9.4 % of these patients had MRSA stains. The
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most common isolated surgical site pathogen was S aureus, which was the cause of 64% of the
infections in the postoperative patients. Of those S. aureus infections, half occurred in the
patients that were identified as nasal carriers. Surgical site infections occurred in 33% of the
patients identified as MRSA carriers (Munoz et al., 2007).

Treatment of Nasal Carriage of MRSA with Mupirocin
Ward and Campoli-Richards (1986) reviewed the antibacterial activity, pharmacokinetic
properties, and therapeutic use of mupirocin. They found that mupirocin 2% ointment
demonstrated excellent efficacy in superficial skin infections with S. aureus and with nasal
carriage of the organism, as well as MRSA. Lanolin-based mupirocin was found to clear the
bacteria within 48 hours in all patients with a treatment regimen of four times daily for five days.
Casewell and Hill’s (1986) study on mupirocin with a soft paragon base, as opposed to the
manufactured glycol base, found that while eradicating the S. aureus in the nares, the glycol base
caused nasal mucosal irritation. Reagan, Doebbleling, Phaffler, Sheetz, Houston, Hollis, and
Wenzel (1991) did a randomized, placebo-controlled study in healthcare workers to evaluate the
effectiveness of Mupirocin ointment and the elimination of S. aureus in nasal and hand carriage.
They cultured the nares at baseline, in 72 hours after treatment with Mupirocin and at 1, 2, 4 and
12 weeks. Mupirocin was effective in eliminating S aureus in the nares for up to 12 weeks
(Reagan et al., 1991). In 2002, Perl, Cullen, Wenzel, Zimmerman, Pfaller, Sheppard, et al. did a
randomized, double-blind, placebo-controlled trail to evaluate if mupirocin was effective in
reducing and preventing S. aureus surgical site infections as well as other nosocomial infections.
In the study, 891 patients, or 23.1% of the patients, had positive S. aureus nasal cultures. This
group was randomized into a mupirocin and placebo group. The infection rate was lower in the
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mupirocin group (4.0%) than in the placebo group (7.7%). They found that prophylactic use of
mupirocin did not significantly reduce S. aureus infections overall, but that it was significant
when used in patients that were nasal carriers of S. aureus. (Perl et al., 2002) A meta-analysis
was done in 2005 by Kallen, Wilson, and Larson from the VA Outcomes Group, Va. and found
that perioperative intranasal mupirocin reduced the risk of surgical site infections in non-general
surgery (cardiac) but had no effect in general surgery patients. Their analysis supports the use of
mupirocin for prevention of surgical site infections in surgeries where the risk of infection with
S. aureus is high (Kallen, Wilson, & Larson, 2005).
In a meta-analysis done by van Rijen, Bonten, Wenzel, and Kluytmans (2009) on the use
of mupirocin ointment for prevention and reductions of S. aureus infections in nasal carriers,
their review showed that the effectiveness of mupirocin in the prevention of S. aureus infections
was related to carriers only. The review suggests the use of intranasal mupirocin eliminates S.
aureus in approximately 80% of patients treated compared to 30% of those treated with placebo
and therefore should be considered in the use of proven nasal carriers pre-operatively (van Rijen
& Kluytmans, 2008). Bode (2009) presented her study at the annual Interscience Conference on
Antimicrobial Agents and Chemotherapy and the Infectious Disease Society of America. In her
trial, conducted in five hospitals in the Netherlands, it was found that by identifying nasal
carriers of S. aureus and following with prompt treatment with mupirocin nasal ointment and
chlorhexidine gluconate medicated soap reduced the risk of infection in those carriers. These
patients were swabbed on the day of admission and started decolonization of carriers within 24
hours. Decolonization was done with mupirocin intranasal twice daily and chlorhexidine total
body washes daily. They repeated this process if the patient remained in the hospital on weeks
three and six. The S. aureus infection rate was 3.4% in the intervention group and was 7.7% in
11

the placebo group and the mean length of stay was lower in the intervention group as well (12
days vs. 14 days) (Bode et al., 2008).

Mupirocin Administration Timing
Mupirocin has been demonstrated in many studies to reduce surgical site infection in
patients that are S. aureus and MRSA positive carriers when administered preoperatively. In
looking at the timing of administration, the STS guidelines recommends beginning treatment
after a positive culture (Richard Engelman et al., 2007). The bactericidal activity of mupirocin
has been shown to cause an inhibition of growth followed by bactericidal activity, which resulted
in 90 to 99% reduction in S. aureus at 24 hours (Parenti, Hatfield, & Leyden, 1987; Ward &
Campoli-Richards, 1986). In Ammerlann, Kluytmans, Wetheim, Nouwen, and Bonten’s (2009)
systematic review, it was suggested that due to the effectiveness of mupirocin immediately
following administration of the drug, beginning treatment in the preoperative period would
eliminate S. aureus and MRSA prior to surgery if administered 24 hours preoperatively
(Ammeriaan, Kluytmans, Wertheim, Nouwen, & Bonten, 2008).

Mupriocin Resistance
Of concern is whether resistance would develop with the use on mupirocin in all
preoperative patients. The Society of Thoracic Surgeons Practice Guidelines recommends using
a PCR rapid analysis and treatment of only positive cultures, but in absence of the rapid PCR
test, the recommendation remains routine prophylaxis for all patients with mupirocin (Engelman
et al., 2007). Mupirocin resistance has been addressed in the literature since 1995. It has been
seen, however rarely, in patients treated long term with mupirocin to prevent hemodialysis or
peritoneal dialysis associated infections (Wenzel & Perl, 1995). In 2005, Fawley, Parnell, Hall,
12

and Wilcox published the results of a four-year point prevalence study on surgery patients and
the use of short-term, empirical, preoperative prophylaxis use of mupirocin in the surgical units
at three hospitals. They did not find any high-level or low-level Mupirocin-resistance isolates.
They examined the isolates phage typing and did not find any mutations or spread of resistant
strains. They did find in long-term follow-up that mupirocin was effective in reducing the
incidence of nasal carriage of MRSA and S. aureus (Fawley, Parnell, Hall, & Wilcox, 2006). In
2006, Shrestha, Banbury, Weber, Cwynar, Lober, Procop, et al. did a retrospective study
evaluating the safety of using targeting preoperative mupirocin in preventing surgical site
infections after cardiac surgery. Nasal cultures were done, and the patients were started on
mupirocin preoperatively. Once the cultures results were available, the mupirocin was
discontinued in the culture negative group. There was no significant difference in the infection
rate between the treated carriers and non-carriers with a relative risk of 1.11. They determined
that providing the mupirocin to the carriers only did not put the non-carriers at increased risk of
surgical site infections in the immediate postoperative period (Shrestha et al., 2006)

Cost Benefit of Mupirocin in Cardiac Surgery
In 1996, VandenBergh, et al. assessed the cost effectiveness of perioperative intranasal
use of mupirocin in cardiothoracic surgery patients. Postoperative costs for a surgical site
infection were estimated to be $16,878, with the incidence of surgical site infection of 7.3%. The
cost of the mupirocin was $11 per patient. The incidences of surgical site infections in the
mupirocin group were significantly decreased to 2.8%. This represented a savings of $16,633,
strongly suggesting that the use of mupirocin was cost effective (VandenBergh et al., 1996).
Cimochowski, Harostock, Brown, Bernardi, Alonzo, and Coyle (2001) conducted a prospective
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study on 992 open-heart surgery patients, examining intra-nasal mupirocin and sternal wound
infections. The study found that the mupirocin group (8 of 854, or 0.9%) had a significant
difference in the rate of overall sternal wound infection than the non-treated group (27 of 992, or
2.7%). The cost of the mupirocin treatment was $12.47 per patient, compared with the cost of a
deep wound infection $81,018 + $41,567 (Cimochowski et al., 2001). On August 1, 2007, the
Centers of Medicare and Medicaid Services (CMS) released the final rule for 2008 hospital inpatient prospective payment system. One of the major changes in the rule is the presence of one
or more preventable complications will not per the patient being allowed to be assigned to a
higher-paying DRG. This rule, thus, cuts the reimbursement to the hospital for patients
experiencing a listed complication. One of the 13 conditions listed in the final rule is
mediastinitis after coronary artery bypass surgery.
Kallen, et al. (2005) found that surgical site infections costs the United States upwards of
$1.6 billion dollars in hospital charges alone and increases hospital stay by approximately five
days (Kallen, et al., 2005). Nicholson and Huesman determined in 2006, when preparing the cost
analysis of their study, that the cost impact of their study, which included the cost of the nasal
culture and the mupirocin, was $45,000 for the anticipated 990 patients needed for the study.
They calculated the average cost of treating a deep sternal wound was $42,766 at the hospital
using 2002 quality control data. When comparing the cost of providing mupirocin for 990
patients to the cost of preventing one sternal wound infection, the cost of the program was
justified (Nicholson & Huesman, 2006).

14

Conclusion of Review of Literature
The literature review synthesis supports the need to test cost effective ways to prevent
surgical infections and the use of mupirocin in the preoperative cardiac surgery patient. It
provides support to provide the same-day admission cardiac surgery patient with 2% mupirocin
nasal ointment and close the gap in care. The nasal mupirocin protocol developed for this project
is supported and based on the evidence as well as the recommendations established by the
Society of Thoracic Surgeons regarding antibiotic prophylaxis (Engelman et al., 2007). The
literature provided an abundance of resources to aid in the development of the data collection
tool needed to look at possible confounding variables with surgical site infections in the cardiac
surgery population in question.
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CHAPTER THREE: METHODS
Research Question
As stated, this study examined the rates of surgical wound infections for preoperative
cardiac patients that came into the Pre-Admission Testing (PAT) unit for preoperative testing
before same-day admission for cardiac surgery and surgical site infections both before and after
initiating an infection prevention protocol of providing 2% mupirocin nasal ointment at no cost
to the patient. The study will determine if a decrease in surgical site infections was observed in
the same-day admission cardiac surgery patients after initiation of provision of mupirocin at no
cost. A related question was how many and what is the rate of same-day admission cardiac
surgery patients who are cultured preoperatively have a positive culture?

Objectives and Aims
The objectives of the proposed study were:
1. To examine the relationship between providing mupirocin to the same-day admission
cardiac surgery patient and the prevalence of surgical site infections. This was done by
comparing the surgical site infection rate for the year prior to implementing the project to
the mupirocin provision group.
2. To examine the cost-effectiveness of providing mupirocin to the same-day admission
cardiac surgery patient and surgical site infections.
3. To examine the adherence of same-day preoperative cardiac surgery patients and the use
of mupirocin preoperatively.

The variables in this study are as follows:
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•

MRSA infection – A surgical site infection that cultures positive with a PCR MRSA test
done in the laboratory. The CDC definition was used to determine MRSA infection.

•

Mupirocin nasal ointment – Medication provided at no cost and administered the night
before surgery (mupirocin 2% 1-gram unit dose) by the patient. Nasal mupirocin calcium
ointment, 2% contains the dihydrate crystalline calcium hemi-salt of the antibiotic
mupirocin. Chemically, it is “((alpha) E ,2 S ,3 R ,4 R , 5 S )-5-[(2 S ,3 S ,4 S ,5 S )-2, 3Epoxy-5-hydroxy-4-methylhexyl] tetrahydro-3,4-dihydroxy-(beta)-methyl-2 H -pyran-2crotonic acid, ester with 9-hydroxynonanoic acid, calcium salt (2:1), dehydrate.” It is
manufactured by DPT Laboratories in San Antonio, Texas and is distributed by
SmithKline Beecham Pharmaceuticals (WebMD, 2008)
(http://www.rxlist.com/bactroban-nasal-drug.htm).

•

Confounding variables that could also influence surgical site infections that were
examined included: demographic variables such as age, gender, discharge situations,
diabetes mellitus (Type 1(DM1) or Type 2 (DM2)), obesity, gender, tobacco use
preoperatively, chronic obstructive pulmonary disease (COPD), presence of preoperative
infection, and the use of a preoperative shower with chlorhexadine gluconate solution.
Laboratory parameters to be examined included hematocrit (HCT), serum creatinine
(Scr), glucosylated hemoglobin (HGBA1C), and positive culture from other sites.
Perioperative factors that were examined included receipt and timing of antibiotics,
redosing of antibiotic, receipt of preoperative steroids, lowest core body temperature
during surgery, transfusion of blood products, and type of cardiac surgery performed.

The level of measurement for the two selected variables is:
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•

Surgical Site infection – This is nominal in level of measurement. If infection is present,
the identified organism is either MRSA or not.

•

Mupirocin nasal ointment – This is nominal in level of measurement as well. The
ointment is either used or not.

The cost of implementing the project and providing the mupirocin will be examined, looking
at the pharmacy costs and labor/supplies. The cost of a sternal wound infection was determined
using the facility accounting program.

Design of Study
This study was quasi-experimental because it is evaluated the effectiveness of the use of
2% mupirocin nasal use in the same-day admission cardiac surgery patient, which changed at a
specific point in time, in reducing MRSA surgical site infection prevalence. This study will
utilize a “non-equivalent control group before and after design” (Pollit & Beck, 2008). This
design allowed for the comparison of two groups of subjects, one examined before the
intervention was implemented (prior to nasal mupirocin provided preoperatively), and one group
examined after the 2% mupirocin nasal ointment was provided. Because the use of nasal
mupirocin is a recommended standard of care for cardiac surgery patients, randomization was
not indicated or possible. The retrospective chart review data was collected on patients that were
processed through PAT for same-day admission for cardiac surgery before and after the practice
change in 2008 through the databases available at the hospital.
Limitations of a study with this design are many. It has been suggested that limitations
include incomparability of the samples being compared in every respect except for the
intervention, because of the lack of randomization. Another limitation is that the study is only
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used patients at one facility, which may influence the generalization of the results although the
sample population is homogeneous (cardiac surgery patients only).
The strength of the design is that it related to practice in the real world. This study is an
evaluation of a process improvement program already in place. Since the provision of mupirocin
was implemented, it is important to evaluate if providing the nasal mupirocin made a difference
(a decrease) in surgical site infection at the facility. In addition, it is important to evaluate if the
provision of mupirocin was an expense that, in reality, paid for itself by preventing the costs that
are incurred from a surgical site infection.

Setting/Sample Population
The setting of this study is a 581-bed tertiary care center in the southeastern United
States.
The subjects in this study were same-day admission cardiac surgery patients of the
cardiothoracic surgeons with privileges to operate at the facility. The inclusion criteria for the
subjects are as follows:
•

18 years of age or older

•

Same-day admission cardiac surgery patient processed through the PAT unit

•

Surgery types: coronary artery bypass graft surgery (CABG), valve surgery, combination
of CABG/valve surgery, and other cardiac surgery patients using PAT such as ASD/VSD
repair and atrial myxomas.

The exclusion criteria included patients undergoing other cardiac surgeries such as aortic
aneurysm repairs, resections, and dissections.
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Access to the patient data was through the PAT unit records and utilizing the facility’s
databases, as this was an evaluation of a process improvement project already implemented.
The sample size was calculated using an online sample size calculator program at the
DSS website. The value to compare the sample percentage to was set at 3% (average surgical site
infection rate according to the literature), and the study sample test value was set at 1% (the
reduction expected in surgical site infection rate; value measured from sample or expected from
sample) and the alpha error level or confidence level of 5% (probability of incorrectly rejecting
the null hypothesis that there is no difference in the percentage values). An Alpha level of 5%
corresponds to a 95% Confidence Interval and with beta error level at 50% (probability of
incorrectly failing to reject the null hypothesis that there is no difference in the percentage values
—assuming no difference when a real difference exists). A Beta of 50% is used in most simple
calculations of sampling error. This program calculated the needed total sample size of 197
subjects (samplehttp://www.dssresearch.com/toolkit/sscalc/size_p1.asp) (DSSResearch, 2006).
In 2008, 775 approximately cardiac surgical procedures were done at the facility. In 2009,
approximately 741 cardiac surgical procedures were done at the facility.

Human Subjects
The study used data already recorded in patient health records. No change in treatment
occurred due to inclusion in this study. The study participants were chosen using a sample of
convenience and the use of nasal mupirocin is a standard of care and not experimental in nature.
The choice to implement the mupirocin protocol was decided in the practice environment,
independent of the research study. There were no costs or additional risks to the patients who
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were included in this study. The study was done to determine whether providing mupirocin at no
cost to the patient was a benefit to the patients and the facility.
Patients who received care after the implementation of the protocol received the nasal
mupirocin at no cost to them. The inclusion of the same-day admission for cardiac surgery in the
standard care recommended by the Society of Thoracic Surgeons (Engelman et al., 2007) and is
provided to the cardiac surgery patients in the hospital preoperatively with the potential to
decrease the risk of developing a MRSA surgical site infection in these patients.
The potential risks of the study to the patients included a possibility of a breach of
confidentiality of personal health information. To prevent such a breach, Health Insurance
Portability and Accountability Act (HIPPA) guidelines were followed. Confidentiality was
maintained by assigning an identification number to each of the patients processed through the
PAT for same-day admission for cardiac surgery. The primary researcher kept this log in a
locked file cabinet. Once the study was completed, the personal health information and
identifiers were destroyed by shredding them. This information will not be shared or reused by
any other person except as required by law or the IRB’s.
The study was submitted to the appropriate Institutional Review Boards (IRB) –
University of Central Florida and the facility. An expedited review was requested, as the risk to
the patient is minimal with the greatest risk being a breach of confidentiality; the Expedited
Review Request Research Involving Human Subjects form was completed and submitted for
review. The study qualified for the expedited review process as the research involved the use of
materials (nasal culture results, medical records) that had been collected for use in treatment of
the patients for the pending cardiac surgery and to provide the standard of care suggested by the
STS guidelines. The Request for Waiver of the Requirements to Consent Subjects or Alteration
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of Consent Elements and HIPAA Waiver Authorization Form was submitted to the IRB’s. The
HIPAA De-Identification Form was submitted as well. IRB approval from the study practice site
was obtained, as well as the University IRB approval.

Instrument/Data Collection Tool
A data collection tool was developed for collection of demographic data and information
regarding confounding variables that may influence development of surgical site infections.
Please see Appendix F for the form. This tool allowed for the collection of demographic data and
information related to the variables under study as well as confounding variables. The data
collection was done by the primary researcher via chart review. The data was entered into the
SPSS 16.0 program by the primary researcher.

Data Analysis
The SPSS 16.0 program was used to perform the data analysis of the study. Because the
level of measurement for the variables is nominal, the statistical tests used in the study will be
non-parametric in nature, Chi Square and the student t-test. The descriptive variables were
measured by percentages within the groups (male/female, MRSA+/MRSA-, and Mupirocin
provided/not provided). The use of Chi Square allows the evaluation of the question that the
actual number of surgical site infections in the same-day admission cardiac surgery patient using
nasal mupirocin with the expected number of surgical site infections in the same-day admission
cardiac surgery patient using mupirocin preoperatively. The expected number was based on the
comparison group of same-day admission cardiac surgery patient that did not receive nasal
mupirocin preoperatively. The assumptions of Chi Square are that the data is frequent in nature,
adequate sample size, measures are independent of each other, and there is a basis for the
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categorization of the variables. The Chi Square uses nominal/categorical data. The first
assumption was met with this study in that the data is frequency; how many MRSA surgical site
infections occurred. The second assumption dealt with the sample size. As the number of sameday admission cardiac surgery patients had increased from 2006 (60) to 2007 (235), a sample
size of 197 was needed in each group. A power analysis was performed to ascertain the needed
sample size (197). The third assumption required that the measures are independent of each
other. This was met as the patient either did receive the medication or did not, and either did
have a MRSA surgical site infection or did not. The fourth assumption was that there is some
theoretical reason for the categories used. This assumption was met by using the variables
chosen at the beginning of the study and not changing the variables to meet the desired outcome.
These are the variables that were needed: the presence of MRSA surgical site infection and the
use of the mupirocin.

Plans
The goal of this project was to determine the effectiveness of provision of mupirocin
prophylaxis to reduce surgical site infections with MRSA in the same-day admission cardiac
surgery patients. If a reduction in the SSIs from the current rate of 2.3% to 1% occurred, the
financial benefit would be examined. Since CMS is no longer reimbursing for mediastinitis after
open-heart surgery, a benefit if the patient develops the wound infection and is it documented the
patient had MRSA positive cultures on admission and was treated appropriately, payment would
occur. Again, we continued to monitor the surgical site infections and benchmark them through
the current protocols and definitions. The only additional monitoring was to determine if the
patient was a same-day admit versus an in-house surgery patient. This data was presented at the
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Cardiovascular Department and Collaborative Practice meetings. The established format of
presentation of the results was continued in the same format so that the stakeholders—surgeons,
nursing, risk management, infection control, and administration—would be able to compare the
results to 2007 data without questions.
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CHAPTER FOUR: RESULTS
This chapter will discuss the sample and the statistical results gathered from the
retrospective chart review. The statistical analysis was completed using the statistical computer
program, SPSS 16.0, Chi square and student t-test. The study sample included patients that were
identified using the facility’s database as being admitted into the PAT for the surgeons
performing cardiothoracic surgery at the facility during the study period. These patient charts
were reviewed to determine eligibility for inclusion in the study.
During the pre-mupirocin provision period from December 2007 to November 2008, in
which the patient did not receive mupirocin or a prescription for mupirocin, the facility’s total
surgical site infection (SSI) rate for the coronary artery bypass graft population was 2.8% (13
infections per 506 procedures performed). See figure 1. While this rate was less than the
National Healthcare Safety Network (NHSN) benchmark of 3.39%, the goal was to lower the
surgical site infection rate.
There were 330 eligible for inclusion. One patient was omitted from the study due to the
chart being closed for review. In this study, 175 patients were processed through the PAT unit
prior to implementation of the provision of mupirocin at no cost to the patient and 154 patients
were in the group to whom mupirocin was provided at no cost. The characteristics of both groups
are summarized in Table 1. Both groups were similar in demographic characteristics, comorbidities, preoperative antibiotics, preoperative care, surgery, postoperative care, and length of
stay. Only hypertension (82.9% vs. 69.5%, p=.0004) and postoperative blood transfusions
(68.6% vs. 49.4%, p=.0001) were higher in the pre-treatment group compared to the mupirocin
group.
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Table 1: Demographic Characteristics of Study Population
Characteristics

Sex:
Male
Female
Age – years
Body mass index
Obesity:
< 25kg/m2
>25kg/m2
>30kg/m2
>35kg/m2
>40kg/m2

No Mupirocin
Provided
Preadmission

Mupirocin Provided
Preadmission

118 (68.2%)
55 (31.8%)
64.1 + 12.2
29.9 + 7.4

99 (64.3%)
55 (35.7%)
64.7 + 10.5
29.9 + 6.2

41 (23.4%)
78 (44.6%)
30 (17.1%)
18 (10.3%)
8 (4.6%)

30 (19.5%)
62 (40.3%)
37 (24.0%)
15 (9.7%)
10 (6.5%)

Table 2: Co-morbidity Characteristics of Study Population
Characteristic

Diabetes:
Type 1
Type 2
Undiagnosed at
admission
Serum glucose,
preoperative mg/dl
HgbA1C, preoperative
Hypertension
Smoking History:
Current smoker
Ex smoker
Never smoked
COPD
Serum creatinine,
preoperative, mg/dl
Steroids, preoperative

No Mupirocin
Provided
Preadmission

Mupirocin Provided
Preadmission

4 (2.3%)
57 (32.6%)
2 (1.1%)

6 (3.9%)
53 (34.4%)
3 (1.9%)

123.4 + 62.4

123.7 + 55.4

6.94 + 1.57
145 (82.9%)

6.81 + 1.36
107 (69.5%)

22 (12.6%)
4 (2.3%)
148 (84.6%)
38 (21.7%)
1.18 + .76

19 (12.3%)
4 (2.6%)
131 (85.1%)
32 (20.8%)
1.06 + .97

2 (1.1%)

1 (0.6%)
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Table 3: Preoperative Care Characteristics:
Characteristic:

Chlorhexidine scrub
used:
Home night before
surgery
Preoperative unit
Positive MRSA
Screen, preoperative

No Mupirocin
Provided
Preadmission

Mupirocin Provided
Preadmission

97 (55.4%)

85 (55%)

67 (38.3%)
0

62 (40.5%)
2 (1.3%)

Table 4: Operative Characteristics of Study Population
Characteristic

Surgery:
CABG
CABG/Valve
Valve
Other
Internal Mammary
Used:
LIMA
RIMA
BIMA
Preoperative
Antibiotics:
Ancef 1 gm
Ancef 2 gm
Vancomycin
None
Antibiotic given prior
to cut, minutes
Antibiotic redosed
after 4 hours
Last core body
temperature in OR,
degrees Celsius
Blood transfusion,
postoperatively

No Mupirocin
Provided
Preadmission

Mupirocin Provided
Preadmission

81 (46.4%)
35 (20.1%)
55 (31.6%)
3 (1.7%)

65 (42.5%)
22 (14.3%)
59 (38.6%)
7 (4.5%)

96 (82.7%)
1 (0.8%)
7 (6.0%)

65 (74.7%)
2 (2.2%)
5 (5.7%)

0
156 (89.7%)
17 (9.8%)
1 (0.6%)
34 minutes + 24

1 (0.6%)
131 (85.1%)
22 (14.3%)
0
32 minutes + 24

105 (60%)

89 (57.7%)

36.2 + .67

36.1 + .86

120 (68.6%)

76 (49.4%)
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Mortality
In the pre-provision of mupirocin group, there was one death (0.6%). In the mupirocin
provided group, there were two deaths (1.3%). None of the deaths in the mupirocin provided
group was attributed to infection and occurred within the first 20 days after surgery.

Table 5: Mortality
PT
ID
9

Surgery
date
5/26

Date of
Death
5/31

34

2/20

3/05

301

7/29

8/17

Cause of Death
CVA, multi
system
Respiratory,
Renal, GI
Arrhythmia
(PEA)

Days after
Surgery
5
13
19

Surgical Site Infections
The first objective of the study was to examine the relationship between providing
mupirocin to the same-day admission cardiac surgery patient and the prevalence of surgical site
infections.
There were five surgical site infections in the pre-provision mupirocin group. There were
no surgical site infections in the mupirocin provided group. Please see Tables 6 -11 for patient
and surgical infection characteristics. There were no differences noted in the choice of
preoperative antibiotics between the groups or re-dosing of antibiotics during the operation (60%
vs. 57.7%). Of note, there were two patients who received antibiotics after the surgical site
incision were made, one in each group. Neither patient developed a surgical site infection.
Operative site infections were diagnosed in the hospital for two patients and after discharge in
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three patients in the pre-provision mupirocin group. All of these infections involved the sternal
wound. There were no repeating or common organisms in the infections. There were no MRSA
or MSSA infections noted in the pre-provision of mupirocin group. The patients who had
surgical site infections had longer length of stay, ranging from five (superficial sternal wound) to
34 days (deep sternal wound). See Table 11 for surgical site infection characteristics and
treatment.

Table 6: Demographic Characteristics of Surgical Site Infection Population
Characteristics
Sex:
Male
Female
Age – years
Body mass index
Obesity:
< 25kg/m2
>25kg/m2
>30kg/m2
>35kg/m2
>40kg/m2

4 (80%)
1 (20%)
65 + 9.13
30.89 + 4.84
2 (40%)
1 (20%)
1 (20%)
1 (20%)
0

29

Table 7: Co-morbidity Characteristics of Surgical Site Infection Population
Characteristic
Diabetes:
Type 1
Type 2
Undiagnosed at admission
Serum glucose, preoperative
mg/dl
HgbA1C, preoperative
Hypertension
Smoking History:
Current smoker
Ex smoker
Never smoked
COPD
Serum creatinine,
preoperative, mg/dl
Steroids, preoperative

0
3 (60%)
0
115.8 + 36.7
6.5 + 1.5
5 (100%)
0
0
5 (100%)
0
2.3 + 2.7
0

Table 8: Preoperative Care of Surgical Site Infection Characteristics:
Characteristic:
Chlorhexidine scrub used:
Home night before surgery
Preoperative unit
Positive MRSA Screen,
preoperative

2 (40%)
1 (20%)
1 (20%)
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Table 9: Operative Characteristics of Surgical Site Infection Population
Characteristic
Surgery:
CABG
CABG/Valve
Valve
Other
Internal Mammary Used:
LIMA
RIMA
BIMA
Preoperative Antibiotics:
Ancef 1 gm
Ancef 2 gm
Vancomycin
None
Antibiotic given prior to cut,
minutes
Antibiotic redosed after 4
hours
Last core body temperature
in OR, degrees Celsius
Blood transfusion,
postoperatively

1 (20%)
1 (20%)
3 (60%)
0
2 (40%)
0
0
0
4 (80%)
1 (10%)
0
40 + 33
3 (60%)
36.3 + .5
4 (80%)

Table 10: Surgical Site Infection Characteristics:
Characteristic:
Surgical Site Infection Diagnosis:
In Hospital
After Discharge
Re-admitted with surgical site infection
Infected surgical site:
Sternal
Organism:
S. aureus
Proteus maribilis
Mycobacterium abscessus
Klesbiella oxytoca
Enterobacter aerogenes

2 (40%)
3 (60%)
3 (60%)
5 (100%)
2*
1
1
1*
1
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Table 11: Characteristics of Patients with Operative Site Infections
ID

Age Gender Surgery

Diagnosed Organism
days after
surgery
CABG
Superficial 29 days
S. epidermiditis
sternal
CABG/MVR Deep
42 days
Mycobacterium
sternal
abscessus

152 57

M

257 72

M

263 76

M

AVR

284 55

M

CABG/AVR

326 65

M

CABG/AVR

Infected
wound

Deep
sternal
Deep
sternal
Deep
sternal

16 days
9 days
14 days

Klebsiella
oxytoca
Enteribacter
aerigenes
Proteus
mirabilis

Antibiotic
therapy

LOS

zosyn

5

Cefoxitin,
biaxin,
bactrim
Rocephin,
cipro
Maxipime,
vancomycin
rocephin
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The patients with surgical site infections were similar in demographic characteristics to
the pre-provision of mupirocin and provided mupirocin group with sex, more males than
females; age (65 + 9.13 vs. 64.1 + 12.2 years), and BMI (30.89 + 4.84 vs. 29.9 + 7.4). In comorbities, in the SSI group 60% were diabetics, Type 2 vs. 32.6% of the pre-provision mupirocin
group. However, the serum glucose on admission was slightly lower (115.8 + 36.7 mg/dl) than
the pre-provision mupirocin group (123.4 + 62.4mg/dl). The entire SSI group had hypertension
vs. the 82.9% of the pre-provision of mupirocin group. The serum creatinine was higher in the
SSI group (2.3 + 2.7 mg/dl) vs. the pre-provision mupirocin group (1.18 + .76). 80% of the SSI
group had valve or combination valve surgery vs. the pre-provision group the majority of the
surgeries were straight coronary artery bypass graft surgeries. The choice of preoperative
antibiotic was predominately the same for both groups – Ancef 2gm IV on induction in operating
room. Antibiotic administration time was similar as well (40 + 33 minutes vs. 34 + 24 minutes).
Core body temperature was similar as well (36.5 + .5 vs. 36.2 + .67 degrees Celsius). Blood
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transfusions were given in 80% of the SSI group and 68.6% of the pre-provision mupirocin
group.

Chlorhexidine Shower
An order for chlorhexidine (CHG) shower the night before and the morning of surgery
was in place prior to implementation of provision of mupirocin at no cost to the patient.
However, noted prior to implementation of the provision of mupirocin that the patients were
being given a different scrub solution than CHG at PAT. This was changed and CHG was given
to the patient at the same time as the mupirocin. There was no difference between the groups in
documentation of the shower the evening prior to surgery (55.4% vs. 55%) and the morning of
surgery (38.3% vs. 40.5%). However, in the patients that developed a SSI, only one patient had
the CHG shower documented as done the evening and morning of surgery and four did not.

Impact of Mupirocin
After completing the chart review and the final analysis of the study using Chi square to
compare the frequency of surgical site infections for the pre-mupirocin and mupirocin provided
groups, a significant difference between the groups was found (X2(1) = 4.497, p < 0.5).
The facility’s infection control program records SSI in the cardiac surgery patient
separately – CBG and other cardiac procedures (MVR, AVR, pericardial window, septal
surgeries) due to the NHSH benchmark is different for these populations.

33

Surgical Site Infections
CABG SSI
Rate
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Figure 1: Surgical Site Infections

As noted in Figure 1, the mean trend line (2.8% rate) indicated that the surgical site infections in
the CABG population only at the facility was below the NHSN benchmark (3.339% rate) prior to
the implementation of provision of mupirocin to the same-day admission open heart patients.
After implementation of provision of mupirocin and correcting the CHG scrub given to the

34

patient in PAT the infection trend line had a significant drop (1.6% rate). This was a 43%
reduction in surgical site infections in coronary artery bypass graft patients at the facility.
In Figure 2, the mean trend line in the other cardiac surgery patients (1.7% rate) indicated
that the surgical site infections in the other cardiac surgery population only at the facility was
above the NHSN benchmark (1.4% rate) prior to the implementation of provision of mupirocin
to the same-day admission open heart patients. After implementation of provision of mupirocin
and correcting, the CHG scrub given to the patient in PAT the infection trend line had a
significant drop (0.4% rate). This was a 75% reduction in surgical site infections in other cardiac
surgery patients at the facility.

NSHS Benchmark 1.3%; 2008 Year End Rate 1.7%; 2009 Year End Rate 0.4%

Figure 2: Other Cardiac Surgery SSI
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Cost Analysis
The second objective was to examine of the cost-effectiveness of providing mupirocin to
the same-day admission cardiac surgery patient. The length of stay (LOS) did not show any
differences between groups. Average LOS for the pre-provision of mupirocin group was 8.38 +
4.45 days and the average LOS for the mupirocin provided group was 8.44 + 4.6 days. The
average LOS of the patient with a surgical site infection was 22.8 + 10.89 days. The average cost
(direct and direct costs) for patients in the pre-provision of mupirocin group was $22,709 and the
mupirocin provided group was $24,350. The average cost (direct and indirect) of the patient with
a surgical site infection was $37,905.

Mupirocin Treatment
The third objective of the study was to examine the adherence of same-day preoperative
cardiac surgery patients with the instruction to use of mupirocin preoperatively. There were 154
patients processed through the PAT during the provision of mupirocin period. The mupirocin
was provided to the patients through the hospital outpatient pharmacy. Review of the medication
dispensed record in the pharmacy and billing records indicated that 111 patients picked up the
medication on the day of PAT (71.4%). Therefore, 44 patients did not pick up the medication per
pharmacy records. The use of the mupirocin the night prior to surgery was not documented in the
preoperative record as medication taken at home in the mupirocin provided patient group.
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CHAPTER FIVE: CONCLUSION
This chapter will discuss the findings of the study related to the study questions,
limitations of the study, conclusions, and implications for nursing as well as recommendations
for further projects related to the outcomes of this study.

Discussion
The first objective of the study was to examine the relationship between providing
mupirocin to the same-day admission cardiac surgery patient and the prevalence of surgical site
infections. This was accomplished by comparing the surgical site infection rate for the year prior
to implementing the provision of mupirocin to the same-day admission cardiac surgery patient.
The reduction of infections found in the mupirocin group was significantly different from
the pre-provision of mupirocin group (X2(1) = 4.497, p < 0.5). This finding supports the study by
VandenBergh et al. (1996) who found a decrease in SSI of 2.8% by implementing mupirocin
preoperatively in cardiothoracic surgery patients. This is supported as well in the study by
Cimochowski, et al. (2001) who had a decrease of SSI in the mupirocin group of 0.9% vs. 2.7%
in the non-mupirocin treated group. The Class I recommendation of the society of Thoracic
Surgeons strongly suggested treatment with mupirocin for patients with positive nasal cultures
(2007). The implementation of this process improvement met the recommendation for treatment
of all the cardiac surgery patients at the facility.
While the STS recommendation is for treating only culture positive patients, this study
provided medication and treated all patients until the culture results were posted. A negative
culture results takes 48 hours to obtain, and a positive culture is able to be diagnosed in 24 hours
using the BBL CHROMagar MRSA test at the facility. In this study, no patients developed an
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adverse reaction to the mupirocin. The average number of doses received in the hospital for the
mupirocin provided group was 2.87 doses + 2. In this study, the two patients that had positive
cultures were treated with five days of mupirocin; however, the preoperative antibiotic choice
was only changed to vancomycin for one patient.
Objective two addressed the cost effectiveness of providing mupirocin to the same-day
admission cardiac surgery patient. This was evaluated by the average cost for the average
hospitalization for the patients, both pre-provision of mupirocin and provision of mupirocin
groups and examination of the cost of care for the SSI patient group compared to the non-SSI in
the pre-provision mupirocin patient group.
There was no difference noted in length of stay (LOS) of the two groups. The average
LOS of the pre-provision of mupirocin group was 8.38 + 4.45 days and for the mupirocin
provided group was 8.44 + 4.6. The average LOS of the surgical site infection group was 22.8 +
10.89 days. This is different from Kallen et al. (2005) who found that SSI increased length of
stay by approximately five days. While this study shows no difference in length of stay between
the two groups, there is a difference in the LOS between the pre-provision of mupirocin group
and the surgical site infection group.
The cost of the average length of stay for the cardiac surgery patient at the facility during
the study period was $22,709 for the pre-provision of mupirocin and $ 24,350 for the provision
of mupirocin group. The average cost of care for the surgical site infection patient was $37,905.
The difference in the hospital costs of the two groups with the provision of mupirocin group
being higher than the pre-provision mupirocin group is more likely related to increased hospital
costs and the global economy rather than the provision of the mupirocin. The cost of providing
the PAT patient with the mupirocin was $4.00. A total of 111 patients picked up the mupirocin at
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the pharmacy, for a total expense of $444.00. The average cost for the SSI patient, when
compared to the pre-provision of mupirocin average cost is 40% higher. Even when compared to
the provision of mupirocin group average cost, the SSI average cost is 36% higher. This supports
Nicholson and Huesman’s (2006) suggestion that the cost of one SSI more than justifies the
expense of providing the mupirocin.
Objective three examined the adherence of same-day preoperative cardiac surgery
patients and the use of mupirocin preoperatively, if provided at no cost. In the hospital, the
nursing staff administers mupirocin the night before surgery and patient adherence to the
treatment regimen is easy to ascertain. For patients coming into the hospital the morning of
surgery, who must self-administer the mupirocin prior to coming into the hospital, the patient
must be educated on the importance of mupirocin, understand how to administer the mupirocin,
and must pick the mupirocin up from the pharmacy. The treatment regimen is dependent on the
patient’s understanding of the importance of the medication and the adherence to therapy.
In this study, only 72.5% of patients in the mupirocin group actually picked up the
mupirocin from the pharmacy. While an obvious solution would be to provide the mupirocin to
the patient in PAT, it is in reality not a solution since mupirocin is a prescription medication and
must be dispensed to the patient according to the rules and regulations of the state for
maintaining and dispensing medications. If the hospital is to continue to supply the mupirocin to
the same-day admission patients at no charge, this failure to adhere to therapy is must be
addressed.
Actual use of the mupirocin was not well documented for the 111 patients that did pick
up the medication from the pharmacy. The SIS electronic medical record program used at the
facility did include a list of all home medications and had good documentation regarding last
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dose of these medications. However, there is no place to document mupirocin used the evening
prior to surgery as a home medication except as part of the narrative note of the nurse.
Documentation of the use of the chlorhexidine (CHG) shower found to have a similar problem.
Therefore, it was not possible to accurately determine adherence with use of the medication of
the patients that did indeed pick up the medication from the pharmacy after PAT.

Identification of Limitations
There are many limitations of this study. These include the lack of randomization by
using a sample of convenience. The use of only one facility limits the ability of generalizing the
results to other cardiac surgery sites. The small sample size is also a limitation. It was determined
that a sample size of 197 patients in each group would be necessary for this study. However, as
this study was retrospective, there were only 330 patients eligible to be included in the study.
The lack of documentation in the SIS system of mupirocin use the evening before surgery for the
patients that picked up the medication led to the assumption that if the patients did pick up the
medication, then they used the medication. This may not be an accurate assumption. The
concurrent change in the pre-operative soap solution to the appropriately ordered CHG soap
solution also limits the study ability to attribute the change in infection rate to mupirocin
provision only.

Conclusions
Munoz et al. (2007) examined the prevalence of MRSA in patients prior to open heart
surgery and found that approximately 27% of patients scheduled for surgery were nasal carriers
of S. aureus, and 9.4% had MRSA strains of s. aureus. Colonization with S. aureus is associated
with increased SSIs due to self-inoculation (Kluytmans et al., 1995). Decolonization with
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mupirocin has been demonstrated to be an effective treatment to prevent SSIs in the cardiac
surgery population (Kallen et al., 2005). This is important if same-day admission patients at this
facility were not receiving the preoperative mupirocin as ordered to prevent a surgical site
infection. If a prescription was given to the patient in the surgeon’s office, prior to the hospital’s
provision of mupirocin, the patient had trouble in finding a pharmacy that carried unit-dose
mupirocin and did not take the medication as prescribed, thereby placing the patient at risk of
developing an SSI.
Surgical site infections can be devastating for cardiac surgery patients, increasing length
of stay, increasing costs of services, and increasing the risk of mortality. Prevention of SSIs are
paramount in this population and is addressed by the Society of Thoracic Surgeons (2007) in the
recommendations for preoperative antibiotics (Ancef or Vancomycin), showering with CHG
prior to surgery and the use of mupirocin if the patient has a positive MRSA nasal culture.
Munoz, et al. (2007) examined patients (337) prior to having open heart surgery and found
approximately 27% were nasal carriers of S. aureus, and 9.4 had the MRSA strain. Van Rijen, et
al. (2008) review of the literature suggests that approximately 30% of patients entering the
hospital are MRSA carriers. This supports the intervention by which all patients are provided
with mupirocin at no cost after the PAT visit. While this study found that only 1.3% of the
mupirocin provided group had positive nasal cultures; this difference might be due to the fact
this study’s cohort was much smaller.
Decolonization of the nasal mucosa prior to open heart surgery needs to started
approximately 24 hours prior to cut time. This means that the patient needs to begin the use the
mupirocin no later than the evening prior to surgery at home.
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The reduction in SSI seen in this study group was significantly more than the previous
year when the patients were provided with a non-CHG soap product and received no mupirocin.
Brode, et al. (2008) in a study, done in five hospitals in the Netherlands, found that MRSA
carrier patients were decolonized with mupirocin and CHG baths. They found that the mupirocin
and CHG group had significantly less SSI (3.4% vs. 7.7%) and LOS was lower as well (12 days
vs. 14 days). This study provided same-day admission patients the mupirocin and CHG soap
solutions and education regarding the use and timing of the shower and administration of drug at
PAT. In this study, CHG shower the night before surgery was documented in the mupirocin
provided group 55%. This was similar to the 55.4% rate found in the pre-provision of
mupirocin/CHG group
Other risk factors that could influence the development of SSI in the cardiac
surgery patients were examined and found to be similar in both groups. The mean age in this
study is 64.7 + 10.5 years, which is similar to Konvalika et al. (2006) finding of 62.5 + 10.8
years and Munoz et al. (2007) finding of 64 years, Cimochowki et al.(2001) finding of 66.1
years. Gender findings are similar as well; more men than women were admitted through the
PAT (64.3% and 35.7% in the mupirocin provided group). Obesity is a risk factor for SSI, and in
this study’s the BMI findings (29.92) were similar to Perl et al. (2002) of 28.9 but higher than
Cimochocwki et al. (2001) of 19.3. Diabetes can affect the surgical patient and wound healing; in
this study, diabetes was found in 42% of the patients in the mupirocin provided group, of which
two were unknown diabetics at admission. This result is higher than Konvalika, et al. (2006) who
reported 28.5% prevalence of diabetes in his treatment group. Nelson and Dries (1986) had a
lower prevalence of diabetics as well, 8.7%. The preoperative orders at this facility include the
measurement of a reflex HBGA1C if the preoperative serum glucose is greater than 120mg/dl.
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The average serum glucose in this study was 123.7 + 55.4mg/dl, which is similar to the nonmupirocin group’s findings of 123.4 + 62.4 mg/dl. The average HGBA1C in this treatment group
was 6.81 + 1.36; however, it was noted that the reflex HGBA1C was not done in five patients in
the total study group. The number of CABG cases included in this study was 42.5% and 46.6%,
and the number of valves included was 38.6% and 31.6%. Combination cases, such as
CABG/Valves were higher in the pre-mupirocin group 20.1% vs. 14.3%.
In evaluating the cost benefit of mupirocin to the cardiac surgery patient, one surgical site
infection is far more costly than the cost of the provision of mupirocin to all the same-day
admission patients. This has been supported by Van den Bergh et al. (1996), Cimochowski et al.
(2001), Kallen et al. (2005), and Nicholson and Huesman (2006) and is confirmed by the average
cost for the pre-provision of mupirocin group compared to the average cost of the surgical site
infection patient, $24,350 vs. $37,905. The cost of the SSI is 40% higher than the non SSIpatient in the pre-provision of mupirocin group. The cost of providing the mupirocin to the 111
patients that picked the medication up at the pharmacy was $444.00. When examining the fact
that no patients in the provision of mupirocin group developed a SSI; the difference between the
cost of the mupirocin and the savings realized by preventing the increased cost of providing care
to the patient is evident.

Implications for Nursing
This study evaluated a process improvement project that was implemented to meet the
recommendations of the Society of Thoracic Surgeons (2007) and to decrease surgical site
infections. This improvement process required collaboration between many departments in the
hospital. Working together with the nurse practitioner coordinating, PAT, outpatient Cardiac
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Rehabilitation department, Preoperative Unit, Pharmacy, Administration, and Security, as a team
was able to develop a process to overcome the perceived barriers of the same- day admission
patient to provide the mupirocin. This collaboration between departments was instrumental in
providing this medication to the same-day admission cardiac patient. This study illustrated the
value of such collaboration by a team, in which a nurse practitioner has a significant role in the
design and implementation of care.
The result of decreased surgical site infections in this population by providing mupirocin
supports the need to address other surgical patient populations that use the PAT. These patients
may benefit from the use of mupirocin, CHG soap solution or both. In the orthopedic population,
for example, the provision of CHG solution or wipes could provide benefit in reducing surgical
site infections and would require collaboration such as this improvement project.
The documentation problems that were discovered during the study were an incidental
finding. The issue had to do with the electronic medical records (EMR) and difficulty
documenting the use of the mupirocin and CHG shower the evening prior to surgery. The PAT
nurses created the home medication list in the EMR and the Preoperative nurse documented the
last dose of the home medication in the EMR, but the mupirocin and CHG were not listed on the
home medication list and therefore the preoperative nurse did not have a cue to raise the question
of the last dose. Identification of needed revisions in the EMR documentation as clinical
processes are changed is essential. Informatics must be involved to assure that documentation
issues are addressed prior to implementation of a study (to be sure needed documentation of
study components can occur using existing forms) and whenever practice process are changed.
Another incidental finding regarding smoking history arose during this study. It was
noted that a large portion of both groups were recorded as never smoked (85.4% and 85.1%)
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compared to the ex-smoker question (2.3% and 2.6%). When looking at the patients with
documented COPD (21.7% and 20.8%), one questions the validity of the smoking history results.
If the nurse asking the question on the history form asks, “Do you smoke?” vs. “Have you ever
smoked?”, the answer would be recorded differently. This is a nursing education issue and will
be addressed with the facility’s unit based educators for staff education and reinforcement.

Recommendations for Further Projects
One of the issues that arose from this study was the lack of 100% patient participation
with the pickup of the mupirocin. This medication was provided at no cost to the same-day
admission cardiac surgery patient. One wonders what the barriers were for the 42 patients that
did not pick up the medication, since cost of the medication was not an issue. A future study may
be warranted to look at the barriers to adherence in this population so to improve the use of the
medication.
A possible confounding variable that made interpretation of the results of this study
difficult was the concurrent correction of the shower solution being provided to the patient at the
same time as the provision of the mupirocin occurred. A study on providing mupirocin, where
the patients are already receiving CHG shower would more clearly evaluate the impact of the
mupirocin as a new intervention.
Diabetic control is important in prevention of surgical site infections in the post openheart patient. In the SSI group, diabetes was documented in 60% of the group. Evaluation of the
glycemic control during the first 48 hours after surgery in the SSI group would be interesting to
examine. If there were periods of hyperglycemia in these patients, the examination of glucose
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management would be indicated for nursing’s’ adherence with the use of the facilities insulin
drip guideline and rate of surgical site infections.
Blood transfusions were noted to be used in 80% of the SSI patients vs. 68.6% of the preprovision of mupirocin group vs. 49.4% in the mupirocin–provision group. Blood transfusions
postoperatively increase the immune response and could potentially increase the risk of SSI.
Examination of the use of blood products in the open-heart surgery patient at the facility and
compared to the STS benchmark for like facilities would be warranted to evaluate the practice
patterns with transfusions.
Pre-operative serum creatinine levels were elevated in the SSI group compared to the preprovision of mupirocin group (2.3 + 2.7 vs. 1.18 + .76). However, the median serum creatinine
level was 1.1. Therefore, were the patients that developed SSIs and had renal insufficiency or
considered end-stage renal disease at a higher risk, and is this specific disease state one that may
have affected the patient’s immune system and pre-disposed them to the development of SSIs?
This relationship needs to be examined more closely.
Another area for future research would be examination of the benefit of providing
no cost CHG to other surgical populations that use the PAT for pre-operative testing, such as
patients having orthopedic surgery. While the use of Mupirocin in other populations is not
supported in the literature, the use of CHG solution is. The provision and education of CHG
solution or wipes could impact the surgical site infections in other surgical populations as well.

Brief Summary
This study examined the impact of the provision of mupirocin to the same-day admission
cardiac surgery patient on surgical site infections. A significant decrease in surgical site
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infections was seen, the mupirocin provided group had no surgical site infections in the year after
beginning the provision of the medication compared to the five surgical site infections seen in
the same-day admission patients processed through the pre-admission testing unit the year prior
to the provision of mupirocin. However, because the provision of CHG solution to the same-day
admission patients was corrected at the same time as the provision of mupirocin the decrease in
surgical site infections cannot be attributed to the mupirocin alone. The decrease in infections
could be related to the mupirocin, the CHG solution, or the combination of both. The facility
demonstrated at 43% reduction in SSI in the total CABG patient population after implementing
the mupirocin for the total population and a 75% reduction in other cardiac surgery total
population—in-house as well as same-day admission patients and the provision of 4% CHG soap
to the same-day admission patients. By utilizing a nurse practitioner lead and a collaborative
team approach to implement this evidence-based practice, the facility and the patients have
benefited.
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Date
9/17/08
9/24/08

9/28/08

Database

Keywords Used

Restrictions to Other
Search
Information
CSA/Illumina Mupirocin/Cardiac None
surgery
Ovid/Medline MRSA
none
Hospital-acquired None
MRSA
MRSA surgical
None
site infections
Cardiac surgery
None
MRSA infections
MRSA
None
prophylaxis
Surgical
None
prophylaxis for
MRSA
Intranasal MRSA None
Mupirocin
None
Mupirocin
None
prophylaxis
Ovid Medline Mupirocin and
None,
Therapeutic uses
Human,
Staph Aur
Thoracic/Cardiac
Human,
surgery
Post-op
complications
Mupirocin and
None
MRSA and
Cardiac surgery
Pubmed
Mupirocin and
None,
MRSA and
English
Cardiac Surgery
Mupirocin
English,
prophylaxis and
Adults
Cardiac surgery
MRSA and
English
Cardiac surgery
Cinahl
Heart surgery and Surgical
mupirocin
wound
infections
Heart surgery and Antibiotic
mupirocin
prophylaxis,
Surgical
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Yield
13
591
437
504
518
592
709

626
438
511
235,
224,
141
25,464,
3,924
5

8,
7
16,
1
14
3,036

10

Date

Database

Keywords Used

Heart surgery and
mupirocin
Heart surgery and
mupirocin
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Restrictions to Other
Search
Information
wound
infections
English, adult

Yield

Staphylococcus
aureus

29
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Authors
Carrier, et al.

Year of
Publication
2002

Clancy, et al.

2006

Engelman, et al.
Fawley, et al.

2007
2005

Jog, et al.

2008

Kallen, et al.

2005

Klevins, et al.

2007

Kluytmans &
Wertheim
Konvalinka, et al.

2004

Laupland & Conly

2003

Martorell, et al.

2004

Mastoraki, et al.

2008

Nicholson &
Huesman

2006

Perl, et al.

2002

Robicsek, A, et al.

2008

Shrestha, et al.

2006

Trautmann, et al.

2007

2006

Article Focus
Use of mupirocin to control and decrease MRSA
after cardiac surgery
Active screening for MRSA as a cost effective
intervention to decrease MRSA infections
Society of Thoracic Surgeons Practice Guidelines
Repeat point-prevalence surveillance regarding
developing mupirocin resistance post operative
Use of PCR screening and treating positive cultures
with mupirocin
Meta-analysis review of intranasal mupirocin and the
prevention of surgical site infections
Population surveillance regarding prevalence of
MRSA in the hospital and community
Overview of nasal carriage of Staphylococcus aureus
and prevention of nosocomial infections
Prophylaxis use of mupirocin post cardiac surgery
and reduction of surgical site infections
Evidence-based Review of treatment of
Staphylococcus aureus colonization and prophylaxis
for infection with topical intranasal mupirocin.
Indentifying and treating outbreaks of MRSA with
intranasal mupirocin does decrease rates of
infections in CBG patients.
Strategy for preventing MRSA in cardiac surgery
patients
Indentifying and treating staphylococcus aureus
carriers with intranasal mupirocin does impact deep
sternal wound infections in cardiac surgery patients.
Treatment with intranasal mupirocin can reduce the
rate of nasal carriage of MRSA and prevention of
postoperative Staphylococcus aureus infections
To examine the effect of 2 expanded surveillance
interventions on MRSA disease – comparing rates of
MRSA clinical disease during and after hospital
admission in 3 consecutive periods (baseline – 12
months, MRSA surveillance for all admission to the
ICU – 12 months, and universal MRSA surveillance
for all hospital admissions – 21 months)
Safety of treating cardiac surgery patients with
intranasal mupirocin
Overview of intranasal mupirocin prophylaxis in
elective surgery – cardiac surgery patients.
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Authors
Tulloch, L.
Ward & CampoliRichards
Wenzel & Perl

Year of
Publication
1954
1986
1995

Article Focus
Compare phage typing of intranasal cultures and
skin/wound cultures in same patient.
A review of mupirocin, its antibacterial activity,
pharmacokinetic properties and therapeutic uses
Significance of nasal carriage of Staphylococcus
aureus and the incidence of postoperative wound
infections
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Authors

Yr
Country
Independent
Pub
Variable
Banbury, M. 2003 USA –Ohio Light
Cycler PCR
assay compared
to the cultureguided treatment
Carrier, M., 2002 Canada
Anti-MRSA
et al.
preventive
measures

Fawley, W,
et al.

2005 UK

Jog, S. et al.

2007 UK

Kallen, A.,
et al.

2005

Klevens, R.,
et al.

2007 USA

Mupirocin
resistance with 5
day perioperative
prophylaxis
regimen
Mupirocin
intranasal

Perioperative
intranasal
mupirocin
Describe the
incidence and
distribution of
invasive MRSA

Depend
Variable
Delay in
treatment
times

Study
Design
Cost benefit/
cost effectiveness
model

Sample
Size
239

Study
Info
If screened +, then treated
with mupirocin for 5 days
with 1gm bid

Sample
Method
convenience

Incidence of
MRSA
infection
after cardiac
surgery
Reduction in
surgical site
infection
with no
MRSA
resistance
Reduction in
surgical site
infection d/t
MRSA for
cardiac
surgery
patients
Reduction in
surgical site
infect-ions
No
differences
in
populations

Retrospective,
case control

13,199

Screened preop, if +
received mupirocin and
vanco IV preop,

convenience

Multi-ward,
prospective

593

Ortho and vascular patients
treated 5 days preop with
mupirocin and tricloan
shower prior to surgery

convenience

Cultures –
latex agglut.

Reliability

Observational
cohort

1,462

Mupirocin for all patients
after MRSA screen on
admission to hospital– d/c
after nag culture, cont for 5
days for + screen

convenience

IDI MRSA
PCR

Reliable
test, results
confirmed
by
additional
cultures

8,987
cases

+ MRSA cases reviewed,

Population
based

Meta-analysis

Multi-site, active,
population based
surveillance in the
Active Bacterial
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Test Used
PCR, discord
result
confirmed
with PNA
FISH test

Valid/
Reliable
reliable

Not
discussed

Authors

Kluytmans,
J, &
Wetheim,
H.
Konvalinka,
A., et al.

Yr
Pub

Country

Independent
Variable
in 9 US
communities and
to estimate the
burden of
invasive MRSA
infections in
USA in 2005
2004 Netherlands Mupirocin use
for MRSA nasal
carriers

Depend
Variable
with
occurrence
of MRSA

Study
Sample
Design
Size
core
surveillance/Emerging
Infections
Program Network.

Surgical site
infections

Review

2006 Canada

Reduction in
surgical site
infect-ions

Random
Double Blinded,
Placebo
controlled

Mupirocin for +
MRSA nasal
carriers only

Laupland,
K., &
Conly, J.
Martorell,
C., et al.

2003 Canada

Nicholson,
M, et al.

2006 USA - Ohio Nasal culture and
nasal mupirocin
bid

2004 USA Mass

Study
Info

Sample
Method

Test Used

Valid/
Reliable

263

Cultured 2 weeks prior to
admission for elective OHS
Mupirocin BID
Chlorhexidine shower
preop and surgical site
cleansing preop
Preop antibix –
cefazolin/clindamycin

convenience

Star-swab

Not
discussed

No culture done, all
convenience
possible cardiac patients
treated with 3 days of nasal
mupirocin and showering
with chlordexidine
All patients cultured,
convenience
intranasal mupirocin started
preop, cont until neg

Oxoid
penicillin
binding

reliable

Evidence-based
Review
Mupirocin
intranasal and
clorhexidine
preop shower

Reduction in
surgical site
infections

Observational

6,465

Reduction in
surgical site
infection

Prospective

1,077
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Authors

Yr
Pub

Country

Independent
Variable

Perl, T, et
al.

2002 USA

Intranasal
mupirocin

Robicsek,
A, et al.

2008 USA

Examine the
effect of 2
expanded
surveillance
interventions on
MRSA

Shrestha,
N., et al.

2006 USA

PCR screening
protocol

Tulloch, L.

1954 UK

Comparing
phage typing of
MRSA intranasal
and infected
wounds

Depend
Variable
after cardiac
surgery

Study
Design

Sample
Size

Reduction of
s. aureus
infection
surgical sites
Reduction in
MRSA
surgical site
infect-ions

Randomized,
double blind,
placebocontrolled
Observational,
multi-site

3,864

Reduction in
Surgical Site
infection
after cardiac
surgery
Common
strain of
MRSA
between
intranasal
culture and
wound

Retrospective
cohort

6,334

Prospective

73 pairs
of
cultures

3,334
ICU pts,
62035
total
hosp-ital
pts
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Study
Info
culture bid, if + then
mupirocin for total of 14
doses, if neg then
mupirocin d/c’d
Screened preop

Baseline year – only
MRSA wound + patients
isolated and treated, no
routine surveillance, Year 3
Cultures taken on all
hospital admission patients,
treated with mupirocin if
culture positive and contact
isolation
Screened prior to surgery
with PCR
Only carriers/+MRSA
nasal culture treated with
mupirocin
Cultures taken from nares
and skin/wound site.

Sample
Method

Test Used

Valid/
Reliable

protein latex
agglutination

PCR3,

Convenience
Informed
consent
waived
convenience

PCR – no
brand

Highly
predictive
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Authors
Carrier, et
al.

Jog, et al.

Year of
Publication
2002

Major Strengths

Major Weaknesses

Conclusions

Very specific, definitions of
infections.
Interventions outlined – preop
screening culture, isolation,
preop antibx IV vanco for +
MRSA nares cultures, culture
results available in 24 hours,
mupirocin started preop, strict
handwashing with alcohol gel,

Retrospective in nature,
Limited to one site
Single preop prophylaxis
given using vanco only,
Preop antibx timing not
reported, DM diagnosis
not included

2008

Observational study
Very specific information
regarding intervention
protocol
Assay information provided
regarding reliability
Infection control policies
provided
Stats used included Chi-

Limited population in
England
Additional medication
used in intervention –
triclosan2%,
Different preop IV
antibiotics used for
prophylaxis – gentamicin
and teicoptanin.

13,199 treated patients,
38 surgical patients with
MRSA infection. 13 with
mediastinitis,
13 with superficial sternal
wound infections, 6 leg
donor site infections,
51 mediastinal infection
with non-MRSA
organism.
Preventive measures
eradicated MRSA
infections 1994-1996, an
outbreak noted after
eradication, preventive
measures reinforced with
handwashing using
alcohol gel added, with
low rates observed.
No significant difference
noted in mortality
Culture done using PCR,
nares swabbed preop,
mupirocin 2% started
preop
Rapid PCR screening is
effective in identifying
nasal colonization with
MRSA in preop cardiac
surgery patients.
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Evidence
Level
2b

1b

Authors

Year of
Publication

Major Strengths

Major Weaknesses

Conclusions

square, Koopman’s likelihoodbased approximation for
relative risk.
Business model predicted
significant savings and was
provided – in British pounds

MRSA
strains/epidemiology and
management differences.
Costs of assay in pounds –
no exchange rate listed
Cost analysis not done,
information not provided

Reduction in culture
turnaround time
significant with PCR vs.
traditional culture
Number of cases of
MRSA was associated
with reduction in SSI’s
but not significant.

Evidence
Level

Kallen, et
al.

2005

Meta- analysis and review of
literature
Studies included randomized
clinical trials, prospective
studies
Patients homogeneous

Limited due to number of
trials included in review
related to inclusion
criteria.
Trials used were nonrandomized.
Missed unpublished
studies.
Baseline usual care
differed between studies
reviewed

Perioperative intranasal
mupirocin appears to
decrease the incidence of
surgical-site infection
when used as prophylaxis
in nongeneral surgery.
Supports the use of
intranasal mupirocin
should be considered.

1a

Klevens,
et al.

2007

Active, population based
surveillance study.
9 sites included in study
Use of Active Bacterial Core
surveillance/Emerging
Infection Program with CDC
Case finding were both active
and laboratory-based
Definitions provided

Results are estimations and
could be underestimated.
Over-estimation could
have occurred in the
community surveillance
due to MRSA not well
documented in medical
records.
Site under surveillance
were urban centers, which

Invasive MRSA affects
certain populations
disproportionately –
obese, diabetics
Not contained to ICU,
acute care hospitals, or
nursing homes.
Un-adjusted incidence
rates approximately 20-50
per 100,000. Incidence

1b
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Authors

Nicholson
&
Huesman

Year of
Publication

2006

Major Strengths

Homogenity with sample
population – cardiac surgery
patients
Prospective study
Methods well outlined –

Major Weaknesses

Conclusions

may lead to an
overestimation regarding
the incidence of MRSA.
Mortality was recorded
from in hospital deaths
thus, deaths could be
underestimated.
Evaluation of the strains
was done in a convenience
sample with a small
sample used (864)

rates consistently higher
in blacks compared with
whites.
Adjusted incidence rate
was 31.8 per 100,000
Health-care associated,
community-onset
infections were greater
than either health careassociated, hospital-onset
infections. Incidence rates
were highest in people >
65 years of age, blacks,
and males.
Standardized mortality
rate was 6.3 per 100,00
Most common health care
risk factors were history
of hospitalization, history
of surgery, long-term care
residence.
Most invasive MRSA
disease is still caused by
MRSA strains of health
care origin.

Convenience sample
Single site
Multiple surgeons
Unknown variables, not
divided by multiple risk

Carrier rate was reported
at 21%.
Decrease in
Staphylococcus aureus
associated SSI observed
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Evidence
Level

2c

Authors

Shrestha,
et al.

Year of
Publication

2006

Major Strengths

Major Weaknesses

Conclusions

Nasal cultured before OR,
intranasal mupirocin
administered and continued
Q12hours. Culture results
returned in 48 hours.
Mupirocin discontinued if
culture negative and continued
for 7 days if culture positive.
PBP2A used for cultured
Stats used – t-test and Chi
square

factors
May have missed
readmission, infections
from patients being
admitted to other facilities.

IRB involvement and waiver
discussed d/t retrospective
design
Methods outlined in detail
Stat methods used included
Large sample size –
homogeneous sample
Preop antibx administration
time included in variables

Retrospective study
Did not include ssi at leg
harvest site
Limited surveillance of
wound infection after
discharge from facility.
Hospitalization length of
stay was variable, followup timing was variable.

from a case rate of 1.68%
to 0.37% per 100
procedures over 17 month
period
Positive results were
confirmed with PFGE –
none of the infections
shared the same strain of
S aureus either from nasal
or wound site
Costs to treat
premupirocin deep sternal
wound estimated to be
$470,000. Estimated
savings $300,000.
Program start up costs
estimated at $45,000
including costs of PCR
and mupirocin.
Prophylaxis antibiotics
included cefazolin,
vancomycin, cefuroxime.
6,334 patients in study
Higher carriers in males
After changing protocol to
discontinue mupirocin if
culture negative – no
increase in surgical site
infections were noted in
the early post op period
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Evidence
Level

2b

Authors

Year of
Publication

Major Strengths

Major Weaknesses
Mupirocin use before
hospitalization/surgery was
not accounted for,
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Conclusions

Evidence
Level

APPENDIX E: MUPIROCIN LITERATURE REVIEW CODES AND MATRIX

64

Code
1
2
3
Code
1
2
3
Code
1
2
3
4
5
Code
1
2
Code
1
2
3
4
5
Code
1
2
3
4
5
6
7

Patient Population
Cardiac surgical
Surgical
Other
Care Setting
Multi-sites/multi-hospitals
Hospital, multiple wards
Hospital, single ward
Mupirocin Regimen
Pre-operative only
On admission to unit
Pre and Post-operatively
Administered for total doses – 5/7
Stopped with negative culture results
Nasal culture for S. aureus before decolonization
Yes
No
Nasal Culture for S. aureus after decolonization
Yes, no time point specified
Yes, 5-7 days after surgery
Yes, months after surgery
No
Not indicated
Topics Presented
General Cardiac Surgery Principles
General Staphylococcus Aureus
General Wound Infection Principles
Methicillin-Resistant Staphylococcus Aureus
Mupirocin – pharmacotherapy principles
Mupirocin – prophylaxis
Cultures, DNA/PCR
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Year of
Population Care Mupirocin Nasal Culture Nasal culture
Topics
Authors
Publication Discussed Setting Regimen
done Preop
done Post
Presented
Banbury, et al.
2003
3 3
1
5 6, 7
Carrier, et al.
2002
1
3 3, 5
1
5 4, 6, 7
Clancy, et al.
2006
3
2 4
1
5 3, 4, 5, 6, 7
Engleman, et al.
2007
1
5 1, 3, 4, 6, 7
Fawley, et al.
2005
3
2 1, 3, 4, 5
1
5 4, 6, 7
Harbarth, et al.
2008
1
3 3
1
5 2,3,5,6,7
Jog
2007
1
3 3, 5
1
2 4, 6, 7
Kallen, et al.
2005
3
1
5 2,4.6.7
Klevens, et al.
2007
3
1
5 4, 7
Kluytmans, et al.
2004
3
1
1
4, 6, 7
Konvalinka, et al.
2006
1
3 3, 5
1
5 4, 6, 7
Laupland & Conly
2003
3
1
5 2,3,5,6,7
Martorell, et al.
2004
1
3 3,5
1
5 4, 6, 7
Mastoraki, et al.
2008
1
3 3, 5
1
5 1, 2, 4, 6, 7
Nicholson, et al.
2006
1
3 3, 5
1
2 4,6 ,7
Parenti, et al.
1987
5
Perl, et al.
2002
3
2
1
5 4, 6, 7
Robicsek, et al.
2008
3
1 6
2 4,7
Shrestha, et al.
2006
1
3 3
1
2 6,7
Streeter, N.
2006
1, 3, 4, 6
Tulloch, L.
1954
7
Ward & Campoli-Richards
1986
5
Weber, et al.
2007
1, 3, 4, 6
Wenzel, & Perl
1995
3
2, 3, 4, 5, 6
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Mupirocin Data Collection Tool
Subject #:________
•

MR# and account information stored separately to meet HIPPA guidelines

Demographic Data:
Age: ________
Marital status:
Other (5)

Gender: Male (1)
Married (1)

Female (2)

Widowed (2) Divorced (3) Separated (4) Significant

Single (6)

Living Situation:

With spouse/SO (1)

Discharge to:

Home (1)

Alone (2)

Other Family (2)

With other family (2) Other (3)
SNF (3)

HHC (4) Expired (5)

Past Medical History/Comorbidities:
Diabetes:

DM1 (1)

HTN: (1)
COPD:

DM2 (2)

Undiagnosed preop (3)

Tobacco Use: Yes – Current (1)
Yes (1)

Yes – recent stopped (2) No (3)

No (2)

Obesity: BMI > 25 kg/m2 (1)

BMI > 30 kg/m2 (2) BMI >35 kg/m2 (3)

BMI > 40

mg/k2 (4) Weight ________#, Height __________inches
Laboratory Data Preoperatively:
Serum creatinine: _______

Serum blood glucose: ______

MRSA/PCR screen done in: PAT (1)

Preop (2)

HBGA1C: ______

Not recorded (3)

Preopmedication:
Steroid use:

Home medication (1) Preop only (2)

Mupirocin 2% documented last dose: Yes (1) No (2) Not documented (3)
CHG Shower night before Yes No
CHG Shower in preop

Yes No
68

Preop antibiotic administered at: ___________
Preop antibiotic selection: Ancef 1 gm (1) Ancef 2 gm (2)
Antibotic Redose: Ancef 1 gm

Vancomycin (3) Clindamycin (4)

Ancef 2 gm

Operative Data:
Surgery done: CBG (1)

CBG/MVR (2)

CBG/AVR (3)

MVR (4)

(5) CBG/AVR/MVR 6
IMA used:

LIMA (1)

RIMA (2)

BIMA (3)

Core body temp: _____
Blood products received:

PRBC (1) # units_______

FFP (2) # units_______

Platelets (3) # units ______ Cryo (4) # units: ________
Cut time/Start time: __________
Postoperative Data:
MRSA/PCR results: Negative (1)

Positive (2)

Results documented/posted at: ________
Mupirocin discontinued at: ___________
Total doses mupirocin received in hospital: ___________
LOS: Admission date: __________________

Discharge date:______________-

Surgical Site Infection Data:
Wound infection noted in hospital:

Yes (1)

No (2)

Wound infection noted after discharge:

Yes (1)

No (2)

Readmitted for wound infection:

Yes (1)

No (2)

Organism grown in wound culture: ____________________
Antibiotic administered: _____________________________
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